Elevar Therapeutics Reports Landmark Median Overall Survival of 23.8 Months in First-Line Treatment for Unresectable Hepatocellular Carcinoma
May 30, 2024 07:00 ET
|
Elevar Therapeutics
Phase 3 CARES-310 study found combination of camrelizumab and rivoceranib continued to show sustained long-term survival compared with sorafenib as a first-line treatment for uHCCFinal analysis...
Elevar Therapeutics To Present Two Posters From Phase 3 CARES-310 Study at 2024 ASCO Gastrointestinal Cancers Symposium
January 18, 2024 08:45 ET
|
Elevar Therapeutics
A post hoc analysis found the efficacy of camrelizumab plus rivoceranib was superior to sorafenib regardless of baseline liver function as measured by both albumin-bilirubin grade and Child-Pugh...
Jiangsu Hengrui Pharma and Elevar Therapeutics Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC
October 17, 2023 09:00 ET
|
Elevar Therapeutics
PRINCETON, N.J. and FORT LEE, N.J. Oct. 17, 2023 (GLOBE NEWSWIRE) -- Jiangsu Hengrui Pharmaceuticals Co., Ltd. (Hengrui Pharma), one of China’s largest pharmaceutical companies based on market...
Elevar Therapeutics and Jiangsu Hengrui Pharma Announce Global Commercialization Licensing Agreement for PD-1 Inhibitor Camrelizumab in Combination with Rivoceranib for uHCC
October 17, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J. and PRINCETON, N.J., Oct. 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and fully integrated biopharmaceutical company dedicated...
Elevar Therapeutics to Host August 10 Virtual KOL Event on Phase 3 Study of Rivoceranib in Combination with Camrelizumab in Unresectable Hepatocellular Carcinoma (uHCC)
August 03, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., Aug. 03, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics Announces Publication of Phase 3 CARES 310 Study Results in The Lancet
July 24, 2023 21:39 ET
|
Elevar Therapeutics
FORT LEE, N.J., July 24, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics Announces FDA Acceptance for Filing of New Drug Application for Rivoceranib in Combination with Camrelizumab as a First-line Treatment for Unresectable Hepatocellular Carcinoma
July 17, 2023 09:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., July 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd., and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics to Participate in ASCO 2023 and BIO 2023; New Jersey-based Company Secures State License as It Builds Toward Commercialization
June 01, 2023 08:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., June 01, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a majority-owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics Submits New Drug Application to FDA for Combination of Rivoceranib and Camrelizumab as First-Line Treatment Option for Unresectable Hepatocellular Carcinoma
May 17, 2023 07:00 ET
|
Elevar Therapeutics
FORT LEE, N.J., May 17, 2023 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a wholly owned subsidiary of HLB Co., Ltd. and a fully integrated biopharmaceutical company dedicated to elevating...
Elevar Therapeutics Announces Positive Pre-NDA Meeting for Rivoceranib Combination With Camrelizumab as Hepatocellular Carcinoma Treatment Option
October 11, 2022 16:00 ET
|
Elevar Therapeutics
SALT LAKE CITY, Oct. 11, 2022 (GLOBE NEWSWIRE) -- Elevar Therapeutics, Inc., a fully integrated biopharmaceutical company dedicated to elevating treatment experiences and outcomes for patients who...